What is Nanodropper?
Founded in 2017, Nanodropper has established itself as a pioneer in pharmaceutical efficiency by developing the only FDA-listed, volume-reducing adaptor for eyedrop bottles. The company addresses a fundamental inefficiency in ocular treatment: the standard eyedrop bottle often dispenses a volume far exceeding what the human eye can absorb, leading to significant medication waste and increased patient costs. By engineering a simple, universal adaptor that attaches to existing bottles, Nanodropper effectively reduces drop size to an optimal level. This innovation not only improves patient compliance and medication affordability but also positions the company as a key player in the intersection of hardware engineering and life sciences. By focusing on high-growth potential within the ophthalmology market, Nanodropper is effectively bridging the gap between clinical necessity and consumer-friendly medical technology.
How much funding has Nanodropper raised?
Nanodropper has raised a total of $1.4M across 1 funding round:
Angel/Seed
$1.4M
Angel/Seed (2021): $1.4M with participation from Golden Seeds, Alliance of Angels, and Rochester Area Chamber of Commerce
Key Investors in Nanodropper
Golden Seeds
A venture capital firm specializing in start-up, early stage, and growth capital investments with a national presence across major US innovation hubs.
Alliance of Angels
Seattle’s leading network of angel investors, providing seed stage investment and strategic support to high-growth startups in the Pacific Northwest.
Rochester Area Chamber of Commerce
A membership organization dedicated to promoting business success through advocacy, networking, and economic development resources.
What's next for Nanodropper?
With the recent influx of capital, Nanodropper is well-positioned to accelerate its commercialization strategy and deepen its market penetration. The company's trajectory suggests a shift from early-stage development toward broader enterprise-level scaling. Future strategic initiatives will likely focus on expanding distribution channels, enhancing manufacturing capabilities to meet rising demand, and potentially exploring new partnerships within the pharmaceutical supply chain. As the company matures, the focus will remain on maintaining its regulatory advantage while scaling its operational infrastructure to support long-term growth in the global eye care market.
See full Nanodropper company page
